BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmitt L, Speckman J, Ansell J. Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range. J Thromb Thrombolysis 2003;15:213-6. [DOI: 10.1023/b:thro.0000011377.78585.63] [Cited by in Crossref: 112] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Chan PH, Hai JJ, Chan EW, Li WH, Tse HF, Wong IC, Lip GY, Siu CW. Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. PLoS One 2016;11:e0150674. [PMID: 27010633 DOI: 10.1371/journal.pone.0150674] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
2 Reiffel JA. Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum. J Innov Card Rhythm Manag 2017;8:2643-6. [PMID: 32494441 DOI: 10.19102/icrm.2017.080302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ko H, Kim HK, Chung C, Han A, Min SK, Ha J, Min S. Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients. Sci Rep 2021;11:5397. [PMID: 33686160 DOI: 10.1038/s41598-021-84868-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Shambu SK, B SPS, Gona OJ, Desai N, B M, Madhan R, V R. Implementation and Evaluation of Virtual Anticoagulation Clinic Care to Provide Incessant Care During COVID-19 Times in an Indian Tertiary Care Teaching Hospital. Front Cardiovasc Med 2021;8:648265. [PMID: 33855052 DOI: 10.3389/fcvm.2021.648265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Panisello-Tafalla A, Clua-Espuny JL, Gil-Guillen VF, González-Henares A, Queralt-Tomas ML, López-Pablo C, Lucas-Noll J, Lechuga-Duran I, Ripolles-Vicente R, Carot-Domenech J, López MG. Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA. Biomed Res Int 2015;2015:134756. [PMID: 26229954 DOI: 10.1155/2015/134756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
6 Lee M, Wang M, Liu J, Holbrook A. Do telehealth interventions improve oral anticoagulation management? A systematic review and meta-analysis. J Thromb Thrombolysis 2018;45:325-36. [PMID: 29350322 DOI: 10.1007/s11239-018-1609-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Qiu S, Wang N, Zhang C, Gu ZC, Qian Y. Anticoagulation Quality of Warfarin and the Role of Physician-Pharmacist Collaborative Clinics in the Treatment of Patients Receiving Warfarin: A Retrospective, Observational, Single-Center Study. Front Pharmacol 2020;11:605353. [PMID: 33519468 DOI: 10.3389/fphar.2020.605353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wang N, Qiu S, Yang Y, Zhang C, Gu ZC, Qian Y. Physician-Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development. Front Pharmacol 2021;12:673302. [PMID: 34177585 DOI: 10.3389/fphar.2021.673302] [Reference Citation Analysis]
10 Liyew Z, Tadesse A, Bekele N, Tsegaye T. Evaluation of Anticoagulation Control among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia. Adv Hematol 2021;2021:7530997. [PMID: 34970315 DOI: 10.1155/2021/7530997] [Reference Citation Analysis]
11 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S-e88S. [PMID: 22315269 DOI: 10.1378/chest.11-2292] [Cited by in Crossref: 941] [Cited by in F6Publishing: 717] [Article Influence: 94.1] [Reference Citation Analysis]
12 Papala M, Gillard D, Hardman J, Romano T, Rein LE. Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic. J Thromb Thrombolysis 2021. [PMID: 34622376 DOI: 10.1007/s11239-021-02566-5] [Reference Citation Analysis]
13 Pengo V, Denas G. Optimizing quality care for the oral vitamin K antagonists (VKAs). Hematology Am Soc Hematol Educ Program 2018;2018:332-8. [PMID: 30504329 DOI: 10.1182/asheducation-2018.1.332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Dalmau Llorca MR, Aguilar Martín C, Carrasco-Querol N, Hernández Rojas Z, Forcadell Drago E, Rodríguez Cumplido D, Pepió Vilaubí JM, Castro Blanco E, Gonçalves AQ, Fernández-Sáez J. Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study). Int J Environ Res Public Health 2021;18:2244. [PMID: 33668315 DOI: 10.3390/ijerph18052244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Barth DD, Zühlke LJ, Joachim A, Hoegger T, Mayosi BM, Engel ME. Effect of distance to health facility on the maintenance of INR therapeutic ranges in rheumatic heart disease patients from Cape Town: no evidence for an association. BMC Health Serv Res 2015;15:219. [PMID: 26041470 DOI: 10.1186/s12913-015-0890-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Lauterbach M, Uhrich E, Eggebrecht L, Göbel S, Panova-Noeva M, Nagler M, Ten Cate V, Bickel C, Espinola-Klein C, Münzel T, Wild PS, Prochaska JH. Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency. J Clin Med 2020;9:E645. [PMID: 32121153 DOI: 10.3390/jcm9030645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 A Reiffel J. Time to Revisit the Time in the Therapeutic Range. J Atr Fibrillation 2017;9:1569. [PMID: 29250280 DOI: 10.4022/jafib.1569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
18 Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation. Am J Cardiovasc Drugs 2015;15:205-11. [PMID: 25944648 DOI: 10.1007/s40256-015-0120-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
19 Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study. BMC Health Serv Res 2017;17:389. [PMID: 28587606 DOI: 10.1186/s12913-017-2330-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Bernaitis N, Ching CK, Badrick T, Anoopkumar-Dukie S. Identifying Warfarin Control With Stroke and Bleed Risk Scores. Heart Lung Circ 2018;27:756-9. [PMID: 29233496 DOI: 10.1016/j.hlc.2017.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
21 Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, Putaala J, Werring DJ. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J 2019;4:198-223. [PMID: 31984228 DOI: 10.1177/2396987319841187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
22 Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, João I, Pereira H. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014;7:891. [PMID: 25491419 DOI: 10.1186/1756-0500-7-891] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
23 Fu G, Wang B, He B, Yu Y, Wang Z, Feng M, Liu J, Du X, Zhuo W, Chu H. Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device. J Formos Med Assoc 2021:S0929-6646(21)00487-3. [PMID: 34740490 DOI: 10.1016/j.jfma.2021.10.015] [Reference Citation Analysis]
24 Mearns ES, Hawthorne J, Song JS, Coleman CI. Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open 2014;4:e005379. [PMID: 24951111 DOI: 10.1136/bmjopen-2014-005379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Farsad BF, Abbasinazari M, Dabagh A, Bakshandeh H. Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study.J Clin Diagn Res. 2016;10:FC04-FC06. [PMID: 27790456 DOI: 10.7860/JCDR/2016/21955.8457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
26 Colet C, Botton MR, Schwambach KH, Amador TA, Heineck I. Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil. J Vasc Bras 2021;20:e20200214. [PMID: 34104133 DOI: 10.1590/1677-5449.200214] [Reference Citation Analysis]
27 Albasri A, Van den Bruel A, Hayward G, McManus RJ, Sheppard JP, Verbakel JYJ. Impact of point-of-care tests in community pharmacies: a systematic review and meta-analysis. BMJ Open 2020;10:e034298. [PMID: 32414821 DOI: 10.1136/bmjopen-2019-034298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Arbring K, Uppugunduri S, Lindahl TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res 2013;13:85. [PMID: 23497203 DOI: 10.1186/1472-6963-13-85] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
29 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
30 Song CG, Bi LJ, Zhao JJ, Wang X, Li W, Yang F, Jiang W. The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study. Int J Med Sci 2021;18:1167-78. [PMID: 33526977 DOI: 10.7150/ijms.52752] [Reference Citation Analysis]
31 Wadell D, Jensen J, Englund E, Själander A. Triple therapy after PCI - Warfarin treatment quality and bleeding risk. PLoS One 2018;13:e0209187. [PMID: 30562365 DOI: 10.1371/journal.pone.0209187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Ting C, Sylvester KW, Schurr JW. Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin. Clin Appl Thromb Hemost 2018;24:178S-81S. [PMID: 30213200 DOI: 10.1177/1076029618798944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clin Cardiol 2018;41:576-85. [PMID: 29542828 DOI: 10.1002/clc.22948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
34 Fatani N, Dixon DL, Van Tassell BW, Fanikos J, Buckley LF. Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. J Am Coll Cardiol 2021;77:1290-9. [PMID: 33706870 DOI: 10.1016/j.jacc.2021.01.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
35 Siddiqui S, DeRemer CE, Waller JL, Gujral JS. Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin. J Innov Card Rhythm Manag 2018;9:3428-34. [PMID: 32494479 DOI: 10.19102/icrm.2018.091203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Santos BB, Heineck I, Negretto GW. USE OF WARFARIN IN PEDIATRICS: CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS. Rev Paul Pediatr 2017;35:375-82. [PMID: 28977131 DOI: 10.1590/1984-0462/;2017;35;4;00008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
37 Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008;28:1084-97. [PMID: 18752379 DOI: 10.1592/phco.28.9.1084] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 7.4] [Reference Citation Analysis]
38 Soyombo BM, Taylor A, Gillard C, Wilson C, Bailey Wheeler J. Impact of body mass index on 90-day warfarin requirements: a retrospective chart review. Ther Adv Cardiovasc Dis 2021;15:17539447211012803. [PMID: 34120532 DOI: 10.1177/17539447211012803] [Reference Citation Analysis]
39 Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. Afr J Prim Health Care Fam Med 2016;8:e1-8. [PMID: 27247158 DOI: 10.4102/phcfm.v8i1.1032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]